CVS Health Corporation (NYSE:CVS) is a prominent player in the healthcare sector, known for its extensive network of pharmacies and healthcare services. The company operates across the United States, providing a range of services from retail pharmacy to health insurance. CVS faces competition from other major healthcare providers like Walgreens and Rite Aid.
On December 10, 2025, Kevin Caliendo from UBS set a price target of $97 for CVS, suggesting a potential increase of approximately 24% from its current price of $78.24. This optimistic outlook aligns with recent analyst upgrades, as highlighted by Wolfe Research, which raised its price target from $85 to $100. The stock opened at $79.14 following this upgrade, reflecting positive market sentiment.
Wolfe Research's "outperform" rating for CVS is echoed by other analysts. Leerink Partners increased their price objective from $86 to $95, maintaining an "outperform" rating. Similarly, Evercore ISI raised their price target from $85 to $95, also assigning an "outperform" rating. These upgrades indicate a strong belief in CVS's growth potential.
Despite the positive outlook from several analysts, Zacks Research recently downgraded CVS from a "strong-buy" to a "hold" rating. This suggests some caution in the market, although the overall sentiment remains optimistic. The stock's current price of $78.24 reflects a 2.23% increase, with a trading volume of 12.58 million shares on the NYSE.
CVS's market capitalization stands at approximately $99.32 billion, indicating its significant presence in the healthcare industry. The stock has fluctuated between a low of $78.22 and a high of $80.50 today, with a 52-week range of $43.56 to $85.15. This volatility highlights the dynamic nature of the stock, influenced by market trends and analyst ratings.
